Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

66
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
66
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

906
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
906
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

69
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

107
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
107
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

539
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
539

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Varicella Zoster Meningitis, Optic Neuritis Preceding the Development of Posterior Outer Retinal Necrosis, and Central Retinal Artery Occlusion in a HIV Patient.

Case reports in medicine·2019
Same author

Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial.

Journal of cardiac failure·2018
Same author

Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review.

JACC. Heart failure·2018
Same author

The Vulnerable Phase of Heart Failure.

American journal of therapeutics·2018
Same author

Optimal Endpoints of Acute Heart Failure Therapy.

American journal of therapeutics·2018
Same author

Improving Postdischarge Outcomes in Acute Heart Failure.

American journal of therapeutics·2018

Related Experiment Video

Updated: Nov 6, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K

SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.

Vishnu Vardhan Garla1,2,3, Javed Butler4, Lillian F Lien5

  • 1Endocrinology, Metabolism and Diabetes, Dept. of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA. vgarla@umc.edu.

Current Cardiology Reports
|May 7, 2021
PubMed
Summary
This summary is machine-generated.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors significantly reduce heart failure mortality and hospitalizations in diabetic patients. These novel agents are now recommended for managing cardiovascular risk in diabetes, offering a new treatment avenue.

Keywords:
Euglycemic diabetic ketoacidosisHeart failureHospitalization for heart failureMajor adverse cardiovascular eventsSodium-glucose cotransporter-2 inhibitors

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.6K

Related Experiment Videos

Last Updated: Nov 6, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.6K

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Heart failure contributes significantly to cardiovascular mortality and morbidity in patients with diabetes mellitus.
  • Sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent a novel class of antidiabetic agents.
  • Recent clinical trials highlight the cardiovascular benefits of SGLT-2 inhibitors.

Purpose of the Study:

  • To review the impact of SGLT-2 inhibitors on heart failure outcomes in diabetic patients.
  • To discuss the role of SGLT-2 inhibitors in managing cardiovascular complications of diabetes.
  • To evaluate the current evidence supporting SGLT-2 inhibitors in heart failure treatment.

Main Methods:

  • Analysis of recent clinical trials focusing on heart failure outcomes.
  • Review of current clinical practice guidelines for diabetes and cardiovascular disease management.
  • Synthesis of data on the efficacy and safety of SGLT-2 inhibitors.

Main Results:

  • SGLT-2 inhibitors demonstrated a significant reduction in cardiovascular death and heart failure hospitalizations.
  • Clinical guidelines now recommend preferential use of SGLT-2 inhibitors in diabetic patients with existing cardiovascular disease.
  • These agents show potential as transformative therapies for heart failure in the diabetic population.

Conclusions:

  • SGLT-2 inhibitors offer substantial benefits in reducing heart failure burden among diabetic individuals.
  • Guidelines facilitate risk-benefit assessment and personalized treatment strategies for SGLT-2 inhibitor use.
  • SGLT-2 inhibitors are pivotal in the evolving landscape of cardiovascular risk management for diabetes.